Exercising on Vyleesi (Bremelanotide): What You Need to Know

How Bremelanotide Works and Why Exercise Matters

Bremelanotide activates melanocortin-4 (MC4) receptors in the central nervous system, modulating pathways involved in sexual desire. The FDA approved it in June 2019 specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Unlike daily medications, Vyleesi is used on an as-needed basis, which gives patients more control over when side effects might occur relative to their workout schedule.

The Cardiovascular Mechanism

The MC4 receptor system also participates in autonomic regulation. Bremelanotide produces a small, dose-dependent rise in blood pressure that peaks roughly 2 to 4 hours after injection and resolves within 12 hours [2]. In the RECONNECT phase 3 trials (Study 301, N=1,247 and Study 302, N=1,213), the mean systolic increase was approximately 6 mmHg and the mean diastolic increase was approximately 3 mmHg [3]. Exercise independently raises blood pressure through increased cardiac output. Stacking a Vyleesi injection on top of a hard training session could, in theory, push systolic readings higher than either stimulus alone.

Why Timing Is the Core Variable

Because Vyleesi is dosed on demand rather than daily, the interaction between the drug and exercise is largely a timing question. A patient who injects at 7 PM for a planned evening and works out at 6 AM the next day faces no pharmacokinetic overlap. A patient who injects at 4 PM and then hits a spin class at 5 PM faces the full overlap window.

Blood Pressure, Heart Rate, and Workout Intensity

The transient hemodynamic changes from bremelanotide are the primary clinical consideration for anyone who exercises regularly. The FDA prescribing information carries a specific warning about the blood pressure elevation and recommends against use in patients with uncontrolled hypertension or known cardiovascular disease [1].

What the Trial Data Show

In the pooled RECONNECT analysis, ambulatory blood pressure monitoring showed that systolic pressure increased by a mean of 6 mmHg, with individual readings occasionally exceeding 10 mmHg above baseline [3]. Heart rate decreased by a mean of 2 to 3 beats per minute. Both effects were transient, resolving well before the next eligible dosing window. No serious cardiovascular events were attributed to bremelanotide across the combined trial population of over 2,400 women [4].

Practical Blood Pressure Thresholds

The American Heart Association defines stage 1 hypertension as a resting systolic reading of 130 to 139 mmHg [5]. For someone with a resting systolic of 125 mmHg, a 6 mmHg drug-induced bump puts them at 131 mmHg before exercise even begins. Add the normal exercise-induced rise (systolic can reach 200+ mmHg during heavy resistance training in normotensive individuals [6]), and the combined peak is modestly higher than it would be without the drug. For most healthy premenopausal women, this additive effect is clinically insignificant. For those with borderline or uncontrolled hypertension, the combination warrants a conversation with a prescribing clinician before establishing a workout routine around Vyleesi.

Heart Rate Considerations

The slight bradycardic effect of bremelanotide (2 to 3 bpm decrease) is unlikely to impair exercise performance. During aerobic training, sympathetic nervous system activation raises heart rate by 40 to 80 bpm above resting levels, easily overriding a 2 to 3 bpm pharmacologic dip. No reports in the RECONNECT trials flagged exercise intolerance or chronotropic incompetence related to bremelanotide [3].

Managing Nausea Around Workouts

Nausea is the most frequently reported adverse event with Vyleesi. In RECONNECT, 40% of bremelanotide-treated patients experienced nausea compared to 1% on placebo [3]. The nausea typically peaks within the first hour after injection and diminishes with repeated use.

The First-Dose Effect

Many patients report that nausea is most pronounced during the first several doses. A 2020 post hoc analysis of the RECONNECT data found that nausea severity declined significantly after the first month of use, with only 22% of patients reporting nausea by month 3 [7]. Starting Vyleesi on a rest day (or at least on a day without planned intense exercise) allows the patient to gauge their personal nausea response before combining the drug with physical activity.

Workout-Specific Strategies

High-impact movements (box jumps, burpees, running) are more likely to aggravate existing nausea than low-impact alternatives (cycling, swimming, walking). If a patient knows they tend to experience nausea with Vyleesi, scheduling workouts outside the 2-hour post-injection window effectively eliminates overlap. Ondansetron 4 mg, taken 30 minutes before injection, has been used off-label by some clinicians to blunt the nausea response, though this approach lacks formal trial data in the bremelanotide context [8].

Building an Exercise Routine While Living With Vyleesi

Regular physical activity improves cardiovascular health, mood, body composition, and, notably, sexual function itself. A 2018 meta-analysis in the Journal of Sexual Medicine (18 studies, N=1,022) found that structured aerobic exercise significantly improved self-reported sexual desire in women [9]. This creates a reinforcing loop: exercise may complement the pharmacologic effect of bremelanotide on HSDD symptoms.

Aerobic Training

Moderate-intensity aerobic exercise (brisk walking, cycling at a conversational pace, elliptical) for 150 minutes per week aligns with the Physical Activity Guidelines for Americans [10]. This type of training produces modest blood pressure elevations that resolve quickly and poses minimal additive risk alongside Vyleesi. Patients who prefer morning workouts and evening Vyleesi dosing will find zero pharmacokinetic conflict between the two activities.

Resistance Training

Heavy compound lifts (squats, deadlifts, bench press) generate the highest acute blood pressure spikes during exertion, particularly during the Valsalva maneuver. Peak systolic readings can exceed 300 mmHg in trained lifters [6]. For Vyleesi patients engaged in heavy resistance training, ensuring at least a 2-hour buffer between injection and lifting provides a reasonable margin. Lighter resistance work (machines, moderate dumbbell circuits, bodyweight movements) produces smaller hemodynamic swings and presents even less concern.

Yoga and Flexibility Work

Yoga, Pilates, and stretching routines carry negligible cardiovascular risk and can be performed at any time relative to Vyleesi dosing. Inversions (headstands, shoulder stands) transiently increase intracranial pressure, but the blood pressure delta from bremelanotide is small enough that standard yoga practices remain safe for otherwise healthy premenopausal women [11].

Long-Term Cardiovascular Safety and Fitness

No long-term cardiovascular outcome trials exist specifically for bremelanotide, which is a common gap for drugs indicated in non-cardiovascular conditions. The available safety data span the 24-week RECONNECT trials plus their open-label extensions.

What the Open-Label Extension Showed

In the open-label extension study (up to 52 weeks of exposure), the hemodynamic profile remained consistent with the placebo-controlled phase: transient blood pressure increases that did not worsen over time and no accumulation effects between doses [4]. No myocardial infarctions, strokes, or heart failure events were attributed to the drug. The total patient-exposure exceeded 4,000 patient-months [4].

Fitness Biomarkers to Monitor

Patients who exercise regularly and use Vyleesi should consider periodic blood pressure monitoring at home, particularly during the first month of Vyleesi use. A home reading taken 1 to 2 hours after injection provides the most clinically relevant snapshot of the additive drug-plus-rest blood pressure. If that reading consistently exceeds 140/90 mmHg, the prescribing clinician should reassess whether Vyleesi remains appropriate [5].

Hyperpigmentation, Sun Exposure, and Outdoor Exercise

Bremelanotide activates MC1 receptors in addition to MC4, which stimulates melanogenesis. In the RECONNECT trials, 1.6% of bremelanotide-treated patients developed focal hyperpigmentation on the face, gingiva, or breasts [3]. The effect was more common in patients with darker baseline skin tones.

Outdoor Workout Precautions

For patients who train outdoors (running, cycling, hiking, outdoor bootcamps), increased melanocyte activity could theoretically interact with UV exposure to accelerate pigmentary changes. No controlled study has specifically evaluated this interaction. Standard sun protection measures (broad-spectrum SPF 30+, UV-protective clothing, avoidance of peak UV hours) are advisable for any patient who notices new pigmentation while on bremelanotide [12]. Patients should report new or changing pigmented lesions to their dermatologist promptly.

Alcohol, Pre-Workout Supplements, and Drug Interactions

The Vyleesi prescribing information does not list a specific alcohol interaction, but alcohol independently lowers blood pressure acutely while raising it chronically and can worsen nausea [1]. Combining alcohol, bremelanotide, and exercise on the same evening creates a triple layer of hemodynamic and gastrointestinal variability.

Stimulant-Based Pre-Workouts

Caffeine and other sympathomimetics found in pre-workout supplements raise blood pressure and heart rate. Adding these on top of a recent bremelanotide injection increases the cumulative blood pressure burden. A 2017 systematic review in Food and Chemical Toxicology found that 400 mg of caffeine can raise systolic blood pressure by 3 to 15 mmHg depending on individual sensitivity [13]. Patients who use both Vyleesi and stimulant-based supplements should separate them by at least 4 hours or discuss the combination with their clinician.

Naltrexone Interaction

Bremelanotide carries a labeled interaction with naltrexone-containing products (including combination bupropion/naltrexone for weight management). Co-administration decreased bremelanotide exposure by approximately 40% in pharmacokinetic studies [1]. Patients taking naltrexone-containing medications for weight loss and also using Vyleesi should be aware that efficacy of both agents may be reduced. This is relevant for patients whose exercise routine is part of a weight management program that includes pharmacotherapy.

When to Talk to Your Prescriber

A few specific scenarios warrant a clinical conversation before continuing to combine Vyleesi with exercise.

Persistent resting blood pressure above 130/80 mmHg on home monitoring within 2 hours of injection signals that the additive effect may be clinically meaningful for that individual [5]. New-onset dizziness or lightheadedness during workouts that only occurs on Vyleesi dosing days could indicate an exaggerated hemodynamic response. Nausea that does not improve after the first 4 to 6 doses and consistently interferes with physical activity may benefit from antiemetic co-therapy or an alternative HSDD treatment such as flibanserin [14]. Any new focal skin darkening, especially on the face or gums, should be documented and evaluated.

The 8-dose monthly cap built into the prescribing information means most patients use Vyleesi on a minority of days each month [1]. On non-dosing days, exercise carries no drug-related considerations at all. This intermittent dosing schedule is, in practice, one of the drug's advantages for active patients.